ACHV is trading 6.6% up at $5.65 as it extends its recovery following a recent FDA setback for its smoking-cessation drug.

  • The stock rose 5.9% on June 24, 2026, as investors digested news that the FDA's non-approval was linked to third-party manufacturing and labeling issues rather than clinical data.
  • Shares continue to trend higher today as the market reassesses the impact of the regulatory delay and the path forward for the treatment.